[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335643-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335643-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","enhancing-lobaplatin-sensitivity-in-lung-adenocarcinoma-through-inhibiting-ldha-targeted-metabolic-pathways-research-article","Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways - research article","","Lung adenocarcinoma (LUAD) is a non-small cell lung cancer subtype with high incidence and mortality, while multidrug resistance limits effective therapy. This study evaluates Lactate dehydrogenase A (LDHA) as a sensitizing factor for Lobaplatin (LBP) chemotherapy. Bioinformatics assessed LDHA in LUAD datasets, and LUAD cell lines A549 and NCL-H1975 received LDHA siRNA or oxamate. LDHA inhibition reduced lactate and ATP while increasing NAD+ and pyruvate, decreasing viability and enhancing LBP sensitivity. PI3K/AKT signaling was implicated, with synergistic tumor-growth inhibition in combined treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/enhancing-lobaplatin-sensitivity-in-lung-adenocarcinoma-through-inhibiting-ldha-targeted-metabolic-pathways-research-article/335643/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/enhancing-lobaplatin-sensitivity-in-lung-adenocarcinoma-through-inhibiting-ldha-targeted-metabolic-pathways-research-article/335643.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study goal regarding LUAD and Lobaplatin?","Question",{"text":63,"@type":64},"To determine whether inhibiting LDHA can enhance the chemotherapy sensitivity of lung adenocarcinoma to Lobaplatin, addressing multidrug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers inhibit LDHA in LUAD cells?",{"text":68,"@type":64},"They used LDHA-targeting siRNA and the small-molecule inhibitor Oxamate in A549 and NCL-H1975 cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"Which metabolic and signaling changes were linked to increased drug sensitivity?",{"text":72,"@type":64},"LDHA inhibition decreased lactate production and ATP levels while increasing NAD+ and pyruvate, and it reduced AKT phosphorylation in the PI3K/AKT pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335643,1790193954,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","PLOS ONE  \nOPEN ACCESS  \nCitation: Yuan S, Ou W, Mi X, Hou J (2024) Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways. PLoS ONE 19(12): e0310825 .  \n[https://doi.org/10.1371/journal.pone.0310825](https://doi.org/10.1371/journal.pone.0310825)  \n[Editor:](Editor: Zhiming Li)[ Zhiming Li](Editor: Zhiming Li), [Columbia University Irving](Columbia University Irving)[ ](Columbia University Irving)Medical Center, UNITED STATES OF AMERICA  \nReceived: June 22, 2024  \nAccepted: September 3, 2024  \nPublished: December 16, 2024  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here:  \n[https://doi.org/10.1371/journal.pone.0310825](https://doi.org/10.1371/journal.pone.0310825)  \n[Copyright:](Copyright:) © [2024 Yuan](2024 Yuan) et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting Information files.  \nFunding: Financial support was provided by Jilin Province Health Commission Project (2021LC058),  \nRESEARCH ARTICLE  \nEnhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHAtargeted metabolic pathways  \nSiyu Yuan1‡, Wenjie Ou2‡, Xuguang Mi3, Junjie Hou4 *  \n1 Department of Clinical Nutrition, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, 2 School of Clinical Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China, 3 Department of central laboratory, Jilin Provincial People’s Hospital, Changchun, Jilin, China, 4 Department of Comprehensive Oncology, Jilin Provincial People’s Hospital, Changchun, Jilin, China  \n‡ SY and WO are contributed equally to this work and should be considered co-first authors.  \n* [houjunjie1979@163.com](houjunjie1979@163.com)  \nAbstract  \nBackground and objective  \nLung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), is associated with high incidence and mortality rates. Effective treatment options are limited due to the frequent development of multidrug resistance, making it crucial to identify new therapeutic targets and sensitizing agents. This study investigates the role of Lactate dehydrogenase A (LDHA) in enhancing the chemotherapy sensitivity of Lobaplatin (LBP) in LUAD.  \nMethods  \nBioinformatics analyses were performed using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to assess LDHA expression in LUAD tissues. LUAD cell lines A549 and NCL-H1975 were treated with siRNA targeting LDHA and the small molecule inhibitor Oxamate. We measured changes in lactate production, ATP levels, NAD+ and pyruvate levels, and assessed cell viability. The chemotherapy sensitivity to Lobaplatin was evaluated, and key signaling pathways related to chemotherapy resistance were analyzed.  \nResults  \nThe inhibition of LDHA resulted in a significant reduction in lactate production and ATP levels, along with an increase in NAD+ and pyruvate levels. These metabolic alterations led to decreased cell viability and enhanced sensitivity to Lobaplatin. The study identified the PI3K/AKT signaling pathway as a critical mediator of this enhanced sensitivity, with reduced phosphorylation of AKT observed upon LDHA inhibition. Furthermore, the combination of LDHA inhibition and Lobaplatin treatment demonstrated a synergistic effect, significantly inhibiting tumor growth and highlighting the potential of LDHA as a therapeutic target to overcome drug resistance in LUAD.  \nPLOS ONE | [https://doi.org/10.1371/journal.pone.0310825](https://doi.","cbCailhFOhyqiUN0","https://ap.wps.com/l/cbCailhFOhyqiUN0","pdf",2850336,16,"English","# Abstract\n## Background and objective\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the study goal regarding LUAD and Lobaplatin?\",\"answer\":\"To determine whether inhibiting LDHA can enhance the chemotherapy sensitivity of lung adenocarcinoma to Lobaplatin, addressing multidrug resistance.\"},{\"question\":\"How did the researchers inhibit LDHA in LUAD cells?\",\"answer\":\"They used LDHA-targeting siRNA and the small-molecule inhibitor Oxamate in A549 and NCL-H1975 cell lines.\"},{\"question\":\"Which metabolic and signaling changes were linked to increased drug sensitivity?\",\"answer\":\"LDHA inhibition decreased lactate production and ATP levels while increasing NAD+ and pyruvate, and it reduced AKT phosphorylation in the PI3K/AKT pathway.\"}]","Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways - research article | PDF",1790011795]